DVA vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DaVita Inc. presents a dichotomy between attractive valuation and precarious financial leverage, anchored by a stable but mediocre Piotroski F-Score of 4/9. While the stock trades at a compelling Forward P/E of 9.26 and a PEG ratio of 0.56, suggesting significant undervaluation relative to growth, this is offset by an extreme Debt/Equity ratio of 11.11 and negative book value. Bearish insider sentiment, characterized by a $199.94M sale, and a weak technical trend (10/100) further temper the bullish case. The stock is currently trading very close to its analyst target price and intrinsic value, leaving limited immediate upside.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
DVA vs LLY: Head-to-Head Comparison
This page compares DaVita Inc. (DVA) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.